VA-CTA
The Consumer Technology Association (CTA)™ Foundation , a national foundation with the mission to link seniors and people with disabilities with technologies to enhance their lives, is proud to announce the winners of the second annual Eureka Park Accessibility Contest: ActiveProtective , Aira , Bansen Labs , BLITAB and KinTrans . The CTA Foundation partnered with Extreme Tech Challenge to collect entries from over 300 startups from around the world. Each winner will receive a booth in Eureka Park during CES® 2017 and a $2,500 cash prize. CES, the gathering place for the global technology industry, runs Jan. 5-8, 2017 in Las Vegas, NV.
“We look forward to witnessing new technologies that provide tools for seniors and people with disabilities, as well as their caregivers, that enable more healthy and independent lives,” said Stephen Ewell, executive director of the CTA Foundation. “Accessibility technology is truly changing lives for the better and will be front and center at CES 2017.”
The winners of the CTA Foundation contest were selected among emerging Eureka Park eligible startups for their innovations that have the potential for a positive impact on older adults and people with disabilities:
- ActiveProtective: Wearable belt that deploys an airbag when a fall is detected to help prevent hip fractures in older adults.
- Aira: Platform that connects blind and low vision individuals with certified virtual agents through wearable devices to assist navigation in everyday life.
- Bansen Labs: First universal adapter that enables individuals to connect their assistive devices to their favorite technologies.
- BLITAB: The world’s first tactile braille tablet that can display an entire page at once without any mechanical elements.
- KinTrans: Sign language translation software designed to provide effective communication between sign language users and those who use spoken language.
The Accessibility Marketplace is the premier marketplace to see how accessible technology is providing tools for individuals with disabilities to live healthy and independent lives. Building on last year’s successful inauguration, the marketplace will see a 50 percent increase in the number of exhibiting companies and return to the 2nd level of the Sands Expo Center in Tech West.
This year’s honorees in the Accessible Tech category of the Innovation Awards - an annual competition honoring outstanding design and engineering in consumer technology products - include Aipoly Vision , Open Sesame! , ReSound ENZO2 , Segina Cellion and 3dRudder . Additionally, there will be two CTA Foundation sponsored conference tracks focused on Accessibility, including Why Accessibility Matters to Tech Leaders and Autonomous Vehicles will Aid Independent Living .
To learn more about the CTA Foundation visit www.CTAFoundation.tech .
Note to Editors: The official name of the global technology event is “CES ® .” Please do not use “Consumer Electronics Show” or “International CES” to refer to the event.
Please note updated CES security measures on CES.tech , including bag check points, bag restrictions and exceptions and badge pickup locations for CES 2017.
About the Consumer Technology Association (CTA) Foundation
The CTA Foundation, a public, national foundation affiliated with the Consumer Technology Association (CTA)™, was launched in 2012 with the mission to link seniors and people with disabilities with technologies to enhance their lives. The foundation strategically supports programs that affect these communities and facilitates dialog between industry, consumers, government, advocacy groups and other key stakeholders. For more information visit CTAFoundation.tech
About Consumer Technology Association:
Consumer Technology Association (CTA)TM , is the trade association representing the $287 billion U.S. consumer technology industry. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. The Consumer Technology Association also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About CES:
CES is the world’s gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years—the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world’s business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .
UPCOMING EVENTS
-
CES Unveiled Las Vegas
January 3, Las Vegas, NV
-
CES 2017 –
Register
January 5-8, Las Vegas, NV
-
Winter Break
March 9-12, Snowmass, CO
-
CES Asia 2017
June 7-9, Shanghai, China
-
CEO Summit
June 21-24, Amalfi Coast, Italy
View source version on businesswire.com: http://www.businesswire.com/news/home/20161129006238/en/
Contact:
Consumer Technology Association
Danielle Cassagnol,
703-907-5253
dcassagnol@CTA.tech
www.CTA.tech
or
Elliot
Grimm, 703-907-5240
egrimm@CTA.tech
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
